KCM
KNSA icon

Kornitzer Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Kornitzer Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Sell
21,369
-722
-3% -$32K 0.02% 389
2025
Q4 		$911K Buy
+22,091
New +$886K 0.02% 420

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Kornitzer Capital Management's KNSA Position: Q1 2026 in Review

Kornitzer Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 3.3% in Q1 2026, selling an estimated $32K and leaving 21,369 shares worth $1.03M. The position accounts for 0.02% of the portfolio, ranked #389.

Kornitzer Capital Management first reported a position in KNSA in Q4 2025 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Kornitzer Capital Management held 21,369 shares of Kiniksa Pharmaceuticals worth $1.03M as of Q1 2026.
  • Kornitzer Capital Management sold 722 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $32K.
  • Kiniksa Pharmaceuticals made up 0.02% of Kornitzer Capital Management's portfolio in Q1 2026, its #389 holding.
  • Kornitzer Capital Management first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Kornitzer Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.